137 related articles for article (PubMed ID: 37545619)
1. Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis.
Fan S; Gai C; Li B; Wang G
Oncol Lett; 2023 Aug; 26(2):351. PubMed ID: 37545619
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
3. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
Chen M; Jiang M; Wang X; Shen L; Li J
Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer.
Li Y; Zhang W; Du J; Hu J; Hu R; Zeng Z; Jin-Si-Han EE; Lian S; Wang H; Li Y; Pan Z; Feng C; Zhang X; Lu Z
Target Oncol; 2024 Apr; ():. PubMed ID: 38691294
[TBL] [Abstract][Full Text] [Related]
5. Case report: Envafolimab causes local skin necrosis.
Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
[TBL] [Abstract][Full Text] [Related]
6. Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia.
Wang L; Mou H; Hou X; Liao Q
Front Oncol; 2023; 13():1126769. PubMed ID: 36998453
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shimizu T; Nakajima TE; Yamamoto N; Yonemori K; Koyama T; Kondo S; Sunakawa Y; Izawa N; Horie Y; Xiang S; Xu S; Qin L; Gong J; Liu D
Invest New Drugs; 2022 Oct; 40(5):1021-1031. PubMed ID: 35932387
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors.
Zhang C; Li J; Wu H; Huang W; Da L; Shen Y; Sun G
Front Pharmacol; 2024; 15():1356013. PubMed ID: 38357311
[TBL] [Abstract][Full Text] [Related]
12. Envafolimab: First Approval.
Markham A
Drugs; 2022 Feb; 82(2):235-240. PubMed ID: 35122636
[TBL] [Abstract][Full Text] [Related]
13. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of the novel combination lenvatinib and pembrolizumab in endometrial cancer: A systematic review and single-arm meta-analysis.
Sultan W; Siddiqui T; Mughal S; Sultan A; Pandey S; Ali Baig MM
Heliyon; 2024 May; 10(9):e30257. PubMed ID: 38720703
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Harb W; Peer CJ; Hua Q; Xu S; Lu H; Lu N; He Y; Xu T; Dong R; Gong J; Liu D
Oncologist; 2021 Sep; 26(9):e1514-e1525. PubMed ID: 33973293
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
[TBL] [Abstract][Full Text] [Related]
19. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
